Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®
N/A
This post marketing observational study (PMOS) was conducted in Japan durin...
Status
Completed
Location
Multiple Locations
Start Date
2013-12
Trial ID
NCT02016690
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
PHASE2
A total of 150 children who meet the entry criteria will be randomized 1:1 ...